Background/Aims: Cardiac fibrosis is a pathological change leading to cardiac remodeling during the progression of myocardial ischemic diseases, and its therapeutic strategy remains to be explored. S100A4, a calcium-binding protein, participates in fibrotic diseases with an unclear mechanism. This study aimed to investigate the role of S100A4 in cardiac fibrosis. Methods: Cardiac fibroblasts from neonatal C57BL/6 mouse hearts were isolated and cultured. Myocardial infarction was induced by ligating the left anterior descending coronary artery (LAD). The ligation was not performed in the sham group. A volume of 5×10 5 pfu/g adenovirus or 5 μM/g ICG-001 was intramyocardially injected into five parts bordering the infarction zone or normal region. We used Western blotting, quantitative RT-PCR, immunofluorescence, immunohistochemistry and Masson's trichrome staining to explore the function of S100A4. Results: We found significant increases of S100A4 level and cardiac fibrosis markers, and β-catenin signaling activation in vitro and in vivo. In addition, knockdown of S100A4 significantly reduced cardiac fibrosis and β-catenin levels. Moreover, the expression of S100A4 decreased after ICG-001 inhibited β-catenin signal pathway. Conclusion: Downregulation of S100A4 alleviates cardiac fibrosis via Wnt/β -catenin pathway in mice. S100A4 may be a therapeutic target of cardiac fibrosis.
Downregulation of S100A4 Alleviates

Introduction
Myocardial infarction (MI) is a major cause of death worldwide [1] . Despite its preventions wildly used, such as statins and new anticoagulants [2] , cardiac remodeling and heart failure still occur after MI [3, 4] . In addition to inflammatory reaction, oxidative Qian et al.: Downregulation of S100A4 Alleviates Cardiac Fibrosis stress and cardiomyocyte apoptosis manifested in cardiac remodeling [5] , cardiac fibrosis is another pathological hallmark [6] that leads to cardiac systolic and diastolic dysfunction [7] . However, therapies for cardiac fibrosis remain unexplored. S100 calcium-binding A4 (S100A4), also named fibroblast-specific protein 1 (Fsp1), is unregulated in fibrotic diseases of lung [8] , liver [9] , kidney [10] and heart [11] . As one member of S100 gene family [12] , S100A4 is involved in cellular processes, especially in cell differentiation and cell growth [13] . However, the role of S100A4 in cardiac fibrosis remains unknown. Wnt/β-catenin signaling pathway is connected with fibroblast activation [14] and tissue repair [15] , including β-Catenin that activates gene transcription [16] and autocrine Wnt ligand production [17] . Stabilized β-catenin activates target genes, like S100A4, a process which leads to aggressive tumor growth, poor prognosis and serious metastasis [18] . No data are available about the mechanism of S100A4 in the Wnt/β-catenin pathway responsible for cardiac fibrosis.
In this experiment, we investigated the expression of S100A4 in hypoxia cardiac fibroblasts and MI murine models, down-regulated S100A4 with adenovirus transfection, and performed ICG-001 treatment to reveal the mechanism of S100A4 in the Wnt/β-catenin signaling pathway in vitro and in vivo.
Materials and Methods
Ethical approval
The research was approved by the ethical committee (Approval No. IACUC-1703039) and carried out according to relevant regulations of Nanjing Medical University. All animal experiments were performed observing to the guidelines published by National Institutes of Health (No. 85-23, revised 1996).
Cell culture
Cardiac fibroblasts (CFs) and myocardial cells (MCs) were isolated from neonatal mice (1-3 days old, Nanjing Medical University Laboratory Animal Center). CFs were cultured in DMEM (GIBCO, Inc., USA) containing 10% fetal calf serum (GIBCO, Inc., USA) and 1% penicillin and streptomycin mixtures (Biyuntian, Inc., China) at 37 °C with 5% CO 2 . The third passage were randomly divided and used in experiments.
Cell transfection S100A4-shRNA (adenovirus to down-regulate S100A4 expression) and Scr-shRNA (adenovirus transfected with scramble siRNA) were synthesized by Shanghai Jikai Gene Technology. After adenovirus transfection in serum free medium for 8 hours, CFs were cultured with complete medium for another 24 hours. Cell growth and GFP expression were observed with a fluorescence microscope and the best multiplicity of infection (2x10 7 pfu/ml) was chosen.
Cell hypoxia
CFs were incubated in GENbag Anaer (Biomerieux SA, France) at 37 °C with a mixture of 5% CO 2 , 1% O 2 and 94% N 2 for 6, 8, 10, 16, and 24 hours respectively.
Surgical preparations
A total of 48 adult male C57BL/6J mice (20-25g) were randomly and equally divided into four groups: sham+Scr-shRNA, sham+S100A4-shRNA, MI+Scr-shRNA and MI+S100A4-shRNA. They were anesthetized through intraperitoneal injection of 1% sodium pentobarbital with the dose of 10 mg/kg. In MI group, the left anterior descending coronary artery (LAD) was ligated. In sham group, the ligation was not performed. Then, a volume of 5×10 5 pfu/g (2.5μl/g, 2x10 7 pfu/ml) S100A4-shRNA or Scr-shRNA was intramyocardially injected into five parts bordering the infarction or normal region. One week after surgery, the mice were sacrificed for histology study.
Western blotting
The whole cell lysates (50 μg) was separated by SDS-PAGE (8% and 10% half-half layered) and transferred to PVDF membranes (0.25 μm, Millipore, Inc., Massachusetts, USA). Having been blocked in 5% BSA at room temperature for 1 hour, the membranes were incubated with proper primary antibodies at 4 °C overnight. Then, secondary antibodies were used to incubate the membranes at 4°C for 2 hours. With potent chemiluminescence kit (Liankebio, Inc., China) and super signal west femto trail kit (Thermo, Inc., USA), the expression of target protein was finally detected. Antibodies used in this study are shown in Table 1 .
Quantitative RT-PCR (qRT-PCR)
Total RNA samples from mice were extracted by TRIzol (Life technologies, Inc., USA). Then, total RNA was reverse-transcribed by a PrimeScript™ RT reagent kit (TaKara Inc., China) for cDNA synthesis. We used a SYBR Premix Ex Taq™ II kit (TaKara Inc., China) for miRNA detection. Gene specific primers were used to amplify S100A4 (forward: 5'-TCCACAAATACTCAGGCAAAGAG-3'; reverse: 5'-GCAGTCCCTGGTCAGTAG-3') and GAPDH (forward: 5'-GGTAAGGTCGGTGTGAACG-3'; reverse: 5'-CTCGCTCCTGGAAGATGGTG-3'). In PCR, preincubation at 95°C for 30 seconds was first performed, followed by 40 cycles of denaturation (95°C for 5 seconds) and annealing (60°C for 30 seconds), and a final dissociation. A StepOnePlus Real-Time PCR System (Applied Biosystems, CA, USA) was used to perform qRT-PCR.
Immunofluorescence
CFs were fixed in 4% paraformaldehyde and then treated with 0.2% triton X-100 for 15 minutes at room temperature respectively. Then, CFs were blocked in 5% BSA at room temperature for one hour and incubated with appropriate primary antibodies at 4°Covernight. Next day, Alexa Fluor 488 nm goat antirabbit lgG (H+L) and Alexa Fluor 594 nm donkey anti-goat lgG (H+L) was added to CFs for one hour. Cell nuclear were stained with DAPI for 10 minutes. We used a software program (Olympus, Japan) and a laser scanning confocal microscope (LSM5, Zeiss, Germany) for image analysis. The cardiac tissues were prepared into 5 μm frozen sections and treated with the similar procedures.
Masson's trichrome staining
The cardiac tissues were respectively fixed in 4% buffered formaldehyde, embedded in paraffin, and then prepared into 5-μm-thick sections. After then, we performed Masson's trichrome staining to investigate the distribution and the extent of the fibrosis. 
Results
Evidence of S100A4 in CFs and MCs
The mRNA and protein expression of S100A4 was detected in CFs and MCs of neonatal mice. We quantified S100A4 mRNA by qRT-PCR (Fig. 1A) and S100A4 protein by Western blotting (Fig. 1B) . Then, CFs were stained red, S100A4 protein stained green and nucleus stained blue by immunofluorescence (Fig. 1C) . The results demonstrated more S100A4 existed in CFs than in MCs.
S100A4 expression increased after hypoxia
According to MTT analysis, cell viability increased gradually at the time points of 0, 6, 8, 10, 16, and 24 hours after hypoxia ( Fig. 2A) . We detected the expression of S100A4 mRNA in CFs by qRT-PCR (Fig. 2B) , and the expression of S100A4 protein by Western blotting (Fig.  2C ). Both expression levels increased went up and peaked at 16 hours after hypoxia. The level of α-SMA (fibrosis indicator) expression increased and peaked at the time point of 24 hours after the hypoxia (Fig. 2D) , demonstrating that hypoxia promoted CFs differentiation. The results suggested that S100A4 participated in cardiac fibrosis after hypoxia.
Downregulation of S100A4 reduced cardiac fibrosis after hypoxia
To reveal the role of S100A4 in cardiac fibrosis, S100A4-ShRNA or Scr-shRNA was transduced into CFs. According to the results of qRT-PCR (Fig. 3A) and Western blotting (Fig. 3B) , the mRNA and protein expression of S100A4 decreased dramatically in S100A4-ShRNA group, which proved the successful downregulation of S100A4 in mice. Compared with Scr-shRNA and Scr-shRNA H group (treated with hypoxia and Scr-shRNA), α-SMA (Fig.  3C ) levels were reduced in S100A4-shRNA H group (treated with hypoxia and S100A4-ShRNA treatment). The results demonstrated that the knockdown of S100A4 inhibited the differentiation of CFs after hypoxia. 
S100A4 expression was elevated after MI
To investigate the function of S100A4 in vivo, murine models were constructed. We investigated the distribution and the extent of the fibrosis by Masson's trichrome staining (Fig. 2E) , which confirmed the successful construction of MI murine model by comparing the normal, infracted, bordering and remote zones. The expression of S100A4 increased significantly in MI murine model by immunofluorescence (IF) and Western blotting ( Fig. 2F and G).
Knockdown of S100A4 alleviated cardiac fibrosis after MI
The level of S100A4 expression markedly reduced in S100A4-ShRNA group according to Western blotting and IF (Fig. 3D and F) , which confirmed the successful knockdown of S100A4 in murine hearts. The level of α-SMA expression obviously dropped (Fig. 3E) . According to IF results (Fig. 3G ), the area with green stained α-SMA in the bordering zone of S100A4-shRNA intramyocardial injection significantly shrunk. The results highlighted that S100A4 downregulation inhibited myofibroblast differentiation in vivo.
β-catenin expression was up-regulated after hypoxia
The expression level of β-catenin increased gradually and peaked at 24 hours after hypoxia (Fig. 4A) , which was consistent with the expression trend of S100A4 after hypoxia.
S100A4 mediated cardiac fibrosis via Wnt/β-catenin pathway after hypoxia
The expression of β-catenin decreased and phosphor-β-catenin elevated in S100A4-ShRNA H group, compared with S100A4-shRNA or Scr-shRNA H group after the transfection of S100A4-shRNA and a 16-hour exposure to hypoxia ( Fig. 4D and E) . In addition, S100A4 expression reduced after ICG-001 and hypoxia treatment in vitro ( Fig. 4G and H) . The results significantly indicated that S100A4 increased cardiac fibrosis via deregulating Wnt/β-catenin pathway.
S100A4 activated cardiac fibrosis via Wnt/β-catenin pathway after MI
The expression level of β-catenin increased in MI mice models ( Fig. 4B and C) , and decreased in S100A4-ShRNA H group compared with S100A4-shRNA or Scr-shRNA H group Fig. 3 . Downregulation of S100A4 reduced the indicators of cardiac fibrosis after hypoxia. (A) According to qRT-PCR, S100A4 mRNA dramatically decreased in S100A4-shRNA group as compared with Scr-shRNA group. (B) S100A4 protein expression also significantly reduced in S100A4-shRNA group by western blot assay. (C) Expression of α-SMA protein reduced in S100A4-shRNA H group in comparison with S100A4-shRNA and Scr-shRNA H group by western blot. (D) The expression of S100A4 markedly reduced in S100A4-ShRNA group according to western blot in vivo. (E) Expression of α-SMA protein was reduced in MI+S100A4-shR-NA group by western blot as opposed with MI+Scr-shRNA and sham+S100A4-shRNA group. (F) S100A4 expression levels dramatically decreased in S100A4-ShRNA group by immunofluorescence. (G) Immunofluorescence showed the reduction of α-SMA in MI+S100A4-shRNA group. Scale bars represent 100 μm; *p<0.05, **p<0.01; n = 6 per group. (Fig. 4F) , while the level of S100A4 expression reduced after intramyocardial injection of ICG-001 in vivo (Fig. 4I) , which were in accordance with the vitro results. IHC showed the level of β-catenin expression decreased in MI+ICG-001 group (Fig. 4J) , demonstrating the positive effect of ICG-001 in MI.
Discussion
This experiment researched the role of S100A4 in cardiac fibrosis through Wnt/β-catenin signaling. Firstly, we verified S100A4 was mainly expressed in CFs rather than MCs ( Fig. 1) . Secondly, as hypoxia continued, the expression levels of S100A4, indicators of cardiac fibrosis and β-catenin all rose dramatically ( Fig. 2 and 4) . Thirdly, knockdown of S100A4 in vitro and in vivo decreased the expression of α-SMA and β-catenin and increased the expression of phosphor-β-Catenin ( Fig. 3 and 4) . Additionally, inhibiting β-catenin signaling by ICG-001 reduced the expression of S100A4 (Fig. 4) , indicating S100A4 may interact with β-catenin via regulating β-catenin phosphorylation and deactivation in cardiac fibrosis. S100A4 is a marker of fibrosis in various cells [7] [8] [9] [10] [11] including CFs and MCs [19] . However, few reports have detailed the S100A4 expression in cardiac fibrosis and verified the efficacy and safety of S100A4 downregulation. Here, we carried out additional experiments to examine the biocompatibility and safety of S100A4 in Fig. 5 . First, MCs from neonatal mice were used to examine the mRNA and protein expression of S100A4 after adenovirus transfection with qRT-PCR (Fig. 5A ) and Western blotting (Fig. 5B) . We found the mRNA and protein expression of S100A4 decreased in S100A4-shRNA group compared with ScrshRNA group. Then with flow cytometry, we detected that the apoptosis of MCs after hypoxia showed no significant difference between S100A4-shRNA and Scr-shRNA group (Fig. 5C) . Also, standard echocardiography results for cardiac morphology and function showed no Fig. 5D and 5E ). The ejection fraction (EF) and fractional shortening (FS) values showed no difference between 0, 7, 14 and 28 day-groups after the surgery. MTT analysis showed cell viability of CFs elevated in S100A4-shRNA group compared to groups of Scr-shRNA or Scr-shRNA H group (Fig. 5F ), which validated the biocompatibility of S100A4-shRNA. To summarize, S100A4 knockdown does no harm to heart and is a biocompatible and safe therapeutic agent. Wnt/β-catenin signaling pathway is a hot field in the research on cardiac fibrosis pathogenesis [20] . S100A4 promotes T-cell factor (TCF) to the binding site in Wnt/β-catenin signaling pathway of cancer cells [17, 21, 22] . But whether this is true to cardiac fibrosis remains to be proven. Since Wnt/β-catenin signaling pathway modulates cytoskeletal dynamics and S100A4 binds heterodimeric β-catenin/TCF complexes [18] , we identified the relationship between S100A4 and Wnt/β-catenin signaling pathway. In this experiment, S100A4 increased the expression of extra nuclear β-catenin protein. Once S100A4 was knocked down, less active β-catenin and more phosphor-β-Catenin proteins were quantified, which demonstrating S100A4 expression was regulated by β-catenin phosphorylation and deactivation. When β-catenin was lowly expressed, the amount of S100A4 dropped. Our results revealed S100A4 activates Wnt/β-catenin signaling pathway in cardiac fibrosis.
Conclusion
Downregulation of S100A4 alleviates cardiac fibrosis via Wnt/β-catenin pathway in mice, which may provide a potential therapeutic target for cardiac fibrosis after MI. More animal experiments, safety assessment and noninvasive myocardial transfection are needed to enhance our findings.
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